Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Gouda, Mohamed A.; Janku, Filip; Yuan, Ying; Drusbosky, Leylah M.; Chen, Alice P.; Zheng, Xiaofeng; Patel, Keyur; Hamilton, Stanley R.; Routbort, Mark; Tricoli, James V.; Williams, P. Mickey; Iafrate, A. John; Sklar, Jeffrey; Coffey, Brent; Little, Richard F.; Arteaga, Carlos L.; O’Dwyer, Peter J.; Flaherty, Keith T.; Harris, Lyndsay N.; Meric-Bernstam, Funda

doi:10.1158/1078-0432.30363438

Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

journal contribution

posted on 2025-10-15, 07:23 authored by Mohamed A. Gouda, Filip Janku, Ying Yuan, Leylah M. Drusbosky, Alice P. Chen, Xiaofeng Zheng, Keyur Patel, Stanley R. Hamilton, Mark Routbort, James V. Tricoli, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F. Little, Carlos L. Arteaga, Peter J. O’Dwyer, Keith T. Flaherty, Lyndsay N. Harris, Funda Meric-Bernstam

<p>Supplementary Table 5. List of alterations of interest that were discordant between tissue and plasma in patients enrolled based on central testing.</p>

Funding

Center for Clinical and Translational Sciences (CTSA)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

History

Related Materials

1.
DOI - Is supplement to Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

ARTICLE ABSTRACT

Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing. We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma. We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n = 243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% (n = 197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n = 32) and had noncontemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allele frequency, and based on tumor biopsy site. The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patient enrollment in trials evaluating biomarker-driven anticancer therapies.See related commentary by Russo et al., p. 4217

Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Funding

Center for Clinical and Translational Sciences (CTSA)

National Cancer Institute (NCI)

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports